SILODOSIN, A NOVEL ALPHA1A AR-SUPER SELECTIVE ANTAGONIST, RAPIDLY IMPROVES BOTHERSOME NOCTURIA IN PATIENTS WHO ARE RESISTANT TO TAMUSULOSIN/NAFTOPIDIL

whether they did or did not report retrograde ejaculation (REj) as an adverse event (AE) during the study. RESULTS: (Table) Of the silodosin (SIL)-treated patients, 335 had no REj (-REj), while 131 had REj (+REj). Baseline IPSS and Qmax were comparable between groups. At 12 weeks, improvements in IPSS (LOCF) and Qmax (LOCF) were significantly greater for SIL(-REj) vs placebo and for SIL(+REj) vs placebo. Improvements in symptoms and peak flow rate were greater in the SIL(+REj) vs the SIL(-REj) group, with a trend toward significance for Qmax. CONCLUSIONS: The 28.1% experiencing retrograde ejaculation with silodosin treatment experienced greater improvement in symptoms and clinically meaningful greater improvement in peak flow rate compared with those not having this effect. This observation suggests that silodosin relaxes the smooth musculature of the lower urinary and genital tracts sufficiently to induce retrograde ejaculation, and that such superior relaxation results in greater objective efficacy in terms of unobstructing patients with LUTS secondary to BPH.